170 related articles for article (PubMed ID: 36561072)
1. Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C.
Stahlecker J; Klett T; Schwer M; Jaag S; Dammann M; Ernst LN; Braun MB; Zimmermann MO; Kramer M; Lämmerhofer M; Stehle T; Coles M; Boeckler FM
RSC Med Chem; 2022 Dec; 13(12):1575-1586. PubMed ID: 36561072
[TBL] [Abstract][Full Text] [Related]
2. Water Leakage Pathway Leads to Internal Hydration of the p53 Core Domain.
Lima IDM; Pedrote MM; Marques MA; Sousa GDS; Silva JL; de Oliveira GAP; Cino EA
Biochemistry; 2023 Jan; 62(1):35-43. PubMed ID: 36535020
[TBL] [Abstract][Full Text] [Related]
3. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.
Wilcken R; Liu X; Zimmermann MO; Rutherford TJ; Fersht AR; Joerger AC; Boeckler FM
J Am Chem Soc; 2012 Apr; 134(15):6810-8. PubMed ID: 22439615
[TBL] [Abstract][Full Text] [Related]
4. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
5. AI-powered discovery of a novel p53-Y220C reactivator.
Zhou S; Chai D; Wang X; Neeli P; Yu X; Davtyan A; Young K; Li Y
Front Oncol; 2023; 13():1229696. PubMed ID: 37593097
[TBL] [Abstract][Full Text] [Related]
6. Embracing the Diversity of Halogen Bonding Motifs in Fragment-Based Drug Discovery-Construction of a Diversity-Optimized Halogen-Enriched Fragment Library.
Heidrich J; Sperl LE; Boeckler FM
Front Chem; 2019; 7():9. PubMed ID: 30834240
[TBL] [Abstract][Full Text] [Related]
7. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
9. Anticancer therapeutic strategies for targeting mutant p53-Y220C.
Chasov V; Davletshin D; Gilyazova E; Mirgayazova R; Kudriaeva A; Khadiullina R; Yuan Y; Bulatov E
J Biomed Res; 2024 May; 38(3):222-232. PubMed ID: 38738269
[TBL] [Abstract][Full Text] [Related]
10. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
11. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.
Bauer MR; Jones RN; Tareque RK; Springett B; Dingler FA; Verduci L; Patel KJ; Fersht AR; Joerger AC; Spencer J
Future Med Chem; 2019 Oct; 11(19):2491-2504. PubMed ID: 31633398
[No Abstract] [Full Text] [Related]
12. Screening of a Halogen-Enriched Fragment Library Leads to Unconventional Binding Modes.
Dammann M; Stahlecker J; Zimmermann MO; Klett T; Rotzinger K; Kramer M; Coles M; Stehle T; Boeckler FM
J Med Chem; 2022 Nov; 65(21):14539-14552. PubMed ID: 36288453
[TBL] [Abstract][Full Text] [Related]
13. Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53
Radhakrishnan N; Dhanjal JK; Sari AN; Ishida Y; Terao K; Kaul SC; Sundar D; Wadhwa R
Discov Oncol; 2021 Dec; 12(1):64. PubMed ID: 35201513
[TBL] [Abstract][Full Text] [Related]
14. Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs.
Bauer MR; Jones RN; Baud MG; Wilcken R; Boeckler FM; Fersht AR; Joerger AC; Spencer J
ACS Chem Biol; 2016 Aug; 11(8):2265-74. PubMed ID: 27267810
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.
Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T
J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418
[TBL] [Abstract][Full Text] [Related]
16. Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.
Han ISM; Thayer KM
ACS Omega; 2024 May; 9(18):19837-19847. PubMed ID: 38737036
[TBL] [Abstract][Full Text] [Related]
17. First-order rate-determining aggregation mechanism of p53 and its implications.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13590-5. PubMed ID: 22869710
[TBL] [Abstract][Full Text] [Related]
18. Quadruple Target Evaluation of Diversity-Optimized Halogen-Enriched Fragments (HEFLibs) Reveals Substantial Ligand Efficiency for AP2-Associated Protein Kinase 1 (AAK1).
Dammann M; Kramer M; Zimmermann MO; Boeckler FM
Front Chem; 2021; 9():815567. PubMed ID: 35186897
[TBL] [Abstract][Full Text] [Related]
19. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.
Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y
Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567
[TBL] [Abstract][Full Text] [Related]
20. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]